Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Bifidobacterium lactis HY8101 decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 18/December/2018, 12.10 am

RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA UCA1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 18/January/2019, 12.04 am
January 17, 2019
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Mevastatin, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1,PDCD4,  p53, p21, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/January/2018, 5.33 pm
January 19, 2019
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests a probiotic-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD).

Bifidobacterium lactis HY8101, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Lactobacillus fermentum DR9 (LF-DR9), either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how Bifidobacterium lactis HY8101 decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Bifidobacterium lactis HY8101 functions as a cholesterol-lowering agent. Bifidobacterium lactis HY8101 lowers cholesterol and triglyceride levels and attenuates NAFLD, through down-regulation of HMGCR

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Bifidobacterium lactis HY8101 decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Bifidobacterium lactis HY8101 decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 18/December/2018, 12.10 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.